




If you would like to share news or information with our readers, please send the unique stories, business

news organization events, and school news to us including your name and phone number in case more information is needed.

For news and information consideration, please send to News@scdaily.com or contact
John Robbins 832-280-5815
Jun Gai 281-498-4310

Mr. Lee's Commentary and Dairy



Inside C2

Southern DAILY

Make Today Different

Southern Daily News is published by Southern News Group Daily

Publisher: Wea H. Lee
President: Catherine Lee
Editor: John Robbins, Jun Gai
Address: 11122 Bellaire Blvd., Houston, TX 77072
E-mail: News@scdaily.com

Wednesday January 13 2021 | www.today-america.com | Southern News Group

U.S. House poised to impeach Trump for second time; McConnell spurns immediate trial



WASHINGTON (Reuters) - As the House of Representatives moved on Wednesday toward a vote to make Donald Trump the first U.S. president to be impeached twice, the Senate's top Republican rejected Democratic calls to reconvene the chamber for an immediate trial, all but ensuring Trump will not be ousted before his term ends next week.

Senate Majority Leader Mitch McConnell has told the chamber's top Democrat Chuck Schumer he is unwilling to call an emergency session to consider removing Trump from office following a House impeachment, a McConnell spokesman said.

The House planned to vote on a single article of impeachment - a formal charge - accusing Trump of "incitement of insurrection" just a week after a pro-Trump mob rampaged through the U.S. Capitol in a deadly attack. The rioters disrupted the formal certification of Democratic President-elect Joe Biden's victory over Trump in the Nov. 3 election and sent lawmakers into hiding. Biden is due to take office on Jan. 20.

The mob acted followed an incendiary speech Trump delivered to thousands of supporters in which he repeated false claims that the election was fraudulent and urged them to march on the Capitol. Five people, including a police officer, died as a result of the violence.

An emotional debate, conducted with extraordinary security inside and outside the Capitol including armed National Guard personnel, unfolded in the same House chamber where lawmakers had crouched under chairs and donned gas masks on Jan. 6 as rioters clashed with police officers outside the doors. "The president of the United States incited this insurrection, this armed rebellion against our common country," House Speaker Nancy Pelosi, a Democrat, said on the House floor. "He must go. He is a clear and present danger to the nation that we all love."

Democratic congressman Julian Castro, a former presidential candidate, called Trump "the most dangerous man to ever occupy the Oval Office." Fellow Democrat Maxine Waters accused Trump of wanting a civil war.

No U.S. president ever has been removed from office through impeachment. Three - Trump in 2019, Bill Clinton in 1998 and Andrew Johnson in 1868 - previously have been impeached by the House but were left in power by the Senate.

Some Republicans argued that the impeachment drive was a rush to judgment that bypassed the customary deliberative process including hearings and called on Democrats to abandon the effort for the sake of national unity. Most Republicans did not actually defend Trump's words or actions.

U.S. Senate's McConnell hasn't decided how he will vote on impeachment
Trump tries to head off new demonstrations among his sup-

porters eaching the president in such a short time frame would be a mistake," said Kevin McCarthy, the House's top Republican. "That doesn't mean the president is free from fault. The president bears responsibility for Wednesday's attack on Congress by mob rioters."

Trump's closest allies, such as Ohio Republican Jim Jordan, went further, accusing Democrats of recklessly acting out of pure political interest.

"This is about getting the president of the United States," said Jordan, who received the Presidential Medal of Freedom from Trump in a private White House ceremony this week. "It's always been about getting the president, no matter what. It's an obsession." A handful of Republicans have said they will support impeachment, including Liz Cheney, the No. 3 House Republican.

Republican Jamie Herrera Beutler said she would vote to impeach Trump, drawing applause from Democrats.

"I am not choosing a side, I'm choosing truth," she said. "It's the only way to defeat fear."

In a break from standard procedure, Republican leaders in the House have refrained from urging their members to vote against impeaching Trump, saying the vote was a matter of individual conscience.

Southern News Group

Please download our APP

- Southern News Group
- Southern News TV



WEA LEE'S GLOBAL NOTES

01/12/2021

CORONAVIRUS DIARY

Wealee@scdaily.com

Professor Lee's Tears

When Professor Esther Lee watched the horrifying video from the U.S. Capitol and was interviewed by our tv host about last Wednesday, she was so sad and tears came to her eyes.

Professor Lee came to America from Taiwan when she was very young. After many years of hard studies she earned her PhD degree and became a well-known education professor at the University of Houston. Because of her enthusiastic spirit to help others, she became involved in community service and joined the Republican Party to serve the community and started a Chinese weekend school to support candidates who were running for public office.

After many years, she got involved in political activities and eventually entered



the U.S. congressional race in the Houston-Clear lake area. Even though she didn't make it, it was the first time the door had been opened to an Asian-American to run for a national post from Texas. Years later she was appointed by President Ronald Reagan and the George Bush administration and went on to serve in the U.S. Department of Education. She was one of very few Asian-Americans who had been appointed to a position

to serve in the federal government. Professor Lee came to America for a better life. After many years of study she earned her PhD degree in education and later taught at the University of Houston and became a very famous and successful scholar. Most immigrants be-

come citizens of this great country, but they never forget where they came from, and they will always be proud as Chinese Asian-Americans and an important part of this great nation.

Professor Lee, we admire you and your contribution to America.



全美政治領袖基金會會長 李恕信

SOUTHERN NEWS GROUP
40th ANNIVERSARY 1979-2019

STV KVVV153
美南國際電視網

Southern News Group Chairman / CEO
Chairman of International Trade & Culture Center
Chairman of International District Houston Texas



Publisher Southern Daily Wea H. Lee

Stay Home!

BUSINESS

Wear Mask!

Promising COVID Research Developments

Two More Life-Saving COVID-19 Drugs Discovered



Two more life-saving drugs have been found that can cut deaths by a quarter in patients who are sickest with Covid.

By Guest Writer Michelle Roberts Health editor, BBC News online

Compiled And Edited By John T. Robbins, Southern Daily Editor

The anti-inflammatory medications, given via a drip, save an extra life for every 12 treated, say researchers who have carried out a trial in NHS intensive care units. Supplies are already available across the UK so they can be used immediately to save hundreds of lives, say experts. There are over 30,000 Covid patients in UK hospitals - 39% more than in April. The UK government is working closely with the manufacturer, to ensure the drugs - tocilizumab and sarilumab - continue to be available to UK patients. As well as saving more lives, the treatments speed up patients' recovery and reduce the length of time that critically-ill patients need to spend in intensive care by about a week. Both appear to work equally well and add to the benefit already found with a cheap steroid drug called dexamethasone. Life-saving coronavirus drug 'major breakthrough' Although the drugs are not cheap, costing around £750 to £1,000 per patient, on top of the £5 course of dexamethasone, the advan-

tage of using them is clear - and less than the cost per day of an intensive care bed of around £2,000, say experts. Lead researcher Prof Anthony Gordon, from Imperial College London, said: "For every 12 patients you treat with these drugs you would expect to save a life. It's a big effect." In the **REMAP-CAP trial** carried out in six different countries, including the UK, with around 800 intensive care patients: Nearly 36% of intensive care COVID patients receiving standard care died. The new drugs reduced that by a quarter, to 27%, when given to patients within 24 of them entering intensive care.



Prof Stephen Powis, NHS national medi-

cal director, said: "The fact there is now another drug that can help to reduce mortality for patients with Covid-19 is hugely welcome news and another positive development in the continued fight against the virus."

Health and Social Care Secretary Matt Hancock said: "The UK has proven time and time again it is at the very forefront of identifying and providing the most promising, innovative treatments for its patients.

"Today's results are yet another landmark development in finding a way out of this pandemic and, when added to the armoury of vaccines and treatments already being rolled out, will play a significant role in defeating this virus."

The drugs dampen down inflammation, which can go into overdrive in Covid patients and cause damage to the lungs and other organs. Doctors are being advised to give them to any Covid patient who, despite receiving dexamethasone, is deteriorating and needs intensive care.

Tocilizumab and sarilumab have already been added to the government's export restriction list, which bans companies from buying medicines meant for UK patients and selling them on for a higher price in another country. The research findings have not yet been peer reviewed or published in a medical journal (Courtesy <https://www.bbc.com/>)

Related

Early Plasma Trial Promising In Adults 65+ With Milder COVID-19 — NNT* of 7 to prevent one case of severe illness in Argentine trial (NNT is a simple statistical concept called the "Number-Needed-to-Treat", or for short the 'NNT'. The NNT offers a measurement of the impact of a medicine or therapy by estimating the number of patients that need to be treated in order to have an impact on one person. The concept is statistical, but intuitive, for we know that not everyone is helped by a medicine or intervention — some benefit, some are harmed, and some are unaffected. The NNT tells us how many of each.)



Older adults hospitalized with milder COVID-19 who received convalescent plasma showed lower risk of developing severe respiratory disease versus patients who received placebo, a randomized trial found. In an intention-to-treat analysis, severe respiratory disease occurred in 16% of COVID-19 patients ages 65 and older receiving convalescent plasma within 72 hours after symptom onset versus 31% of patients receiving placebo (relative risk 0.52, 95% CI 0.29-0.94, P=0.03), reported Fernando Polack, MD, of Fundación INFANT-COVID-19 Group in Buenos Aires, Argentina, and colleagues, in the New England Journal of Medicine.

However, the trial was stopped early at about three-quarters of its projected sample size due to a decline in COVID-19 cases in the region, the authors noted. Evidence for convalescent plasma in COVID-19 has been conflicting from the beginning. Some observational studies showed promise, while more recent research found no benefit among patients with severe COVID-19. But previous studies may have administered them too late, as authors noted antibodies in plasma "must be administered soon after infection in order to be effective." The FDA authorized its use in hospitalized COVID-19 patients in August.

Polack and colleagues pointed up how their trial differed from others: it focused on older adults, who are most affected by the pandemic, and convalescent plasma was given "in a mild stage" with the aim of preventing progression.

"Our primary endpoint" -- severe respiratory illness -- "was an enrollment criterion in previous studies," the group noted. Patients were enrolled in Argentina from June 4 to Oct. 25. They included patients ages 65-74 with at least one comorbidity, and patients ages 75 and older irrespective of pre-existing conditions. They had tested positive for SARS-CoV-2 and had symp-

toms including fever, unexplained sweating or chills and dry cough for less than 48 hours. Severe respiratory disease was defined as respiration at 30 breaths per minute or more or oxygen saturation of less than 93% on ambient air. They were assessed from 12 hours after infusion to day 15 of trial participation.



Overall, 160 patients underwent randomization. Mean age was 77, and 62% were women. A little more than half were 75 or older. Most patients had pre-existing conditions, with over two-thirds of both groups being treated for hypertension. An intention-to-treat analysis found severe respiratory disease developed in 13 of 80 patients in the intervention group and 25 of 80 in the placebo group, for a relative risk reduction of 48% and a number needed to treat of 7 to avert one episode of severe respiratory disease.

There were no solicited adverse events observed. Four convalescent plasma recipients had life-threatening respiratory disease. Two patients in the intervention group and four patients in the placebo group died.

Polack's group noted that while the trial "lacked the statistical power to discern long-term outcomes," their findings underscored "the need to return to the classic approach of treating viral infections early."

An exploratory finding of the trial was a dose-dependent IgG effect, where donated plasma with IgG titers of 1:3,200 or higher reduced severe respiratory disease by 73% and a number needed to treat of 4. Among the plasma donors in the trial, 71% with titers of 1:3,200 or higher were previously hospitalized.

"Super donors' with IgG titers of 1:12,800 or higher and perhaps immunized persons in the future could contribute to build a therapeutic arsenal," Polack and colleagues wrote. (Courtesy [medpagetoday.com](https://www.mcgill.ca/medpagetoday.com))

Editor's Choice



President Donald Trump waves as he departs the White House on travel to visit the U.S.-Mexico border Wall in Texas. REUTERS/Kevin Lamarque



General view of the Helsinki Cathedral during a heavy snow storm in Helsinki, Finland. Vesa Moilanen/Lehtikuva



Activists in opposition to the death penalty gather to protest the execution of Lisa Montgomery, who is scheduled to be the first woman put to death by the federal government in nearly 70 years, at the United States Penitentiary in Terre Haute, Indiana. REUTERS/Bryan Woolsto



Members of the National Guard gather at the U.S. Capitol as the House of Representatives prepares to begin the voting process on a resolution demanding Vice President Pence and the cabinet remove President Trump from office, in Washington. REUTERS/Erin Scott



A healthcare worker takes a nasal swab sample from a migrant worker for a COVID test at a market in Pathum Thani province, Thailand. REUTERS/Athit Perawongmetha



Gompo Yarmolinsky with the Architect of the Capitol cleans dust from the bust of Martin Luther King, Jr. in the Capitol Rotunda after supporters of President Trump stormed the U.S. Capitol in Washington. REUTERS/Joshua Roberts



A woman walks while carrying pineapples on her head on a street in Kampala, Uganda. REUTERS/Baz Ratner



Protesters shout slogans during a demonstration against the Israeli Prime Minister Benjamin Netanyahu's alleged corruption, the postponement of his trial and his handling of the coronavirus crisis, outside his residency in Jerusalem. REUTERS/Ronen

Moderna Vaccine May Work For ‘A Couple Of Years’



Compiled And Edited By John T. Robbins, Southern Daily Editor

Jan. 8, 2021 -- The Moderna vaccine -- one of two vaccines now being distributed in the United States -- will “potentially” provide protection against COVID-19 for several years, the biotech company’s CEO said, according to Reuters. But Stephane Bancel said the Massachusetts-based Moderna will have to conduct more research to be definitive about how long the vaccine will work. Because coronavirus vaccines are new, health experts aren’t sure how long they’ll be effective. “The nightmare scenario that was described in the media in the spring with a vaccine only working a month or two is, I think, out of the window,” Bancel said at an event organized by the Franco-German financial services group Oddo BHF. “The antibody decay generated by the vaccine in humans goes down very slowly (...) We believe there will be protection potentially for a couple of years.” Bancel went on to predict Moderna would soon prove its vaccine would work against coronavirus variants found in the United Kingdom and other nations, Reuters said. The U.S. government approved the Moderna vaccine for distribution in the United States on Dec. 17, one week after approving the Pfizer/BioNTech vaccine. Both are now being administered in the United States and the Moderna vaccine was recently approved by the European Com-

mission. Moderna and Pfizer both use two shots of messenger RNA to create an immune response against the coronavirus. The shots are given about two weeks apart.



Moderna said its vaccine had proven to be 94.1% effective, and 100% effective in severe cases of COVID-19. Pfizer says its vaccine has a similar efficacy, 95%. The U.S. Department of Health and Human Services has agreed to purchase 200 million doses of Moderna’s vaccine and could purchase more. Despite increasing coronavirus case counts and deaths, distribution of the coronavirus vaccine has lagged in the United States. The CDC says 17.2 million doses have been distributed to the states as of Dec. 6, but only 5.3 million doses have been administered. Vaccines being produced by AstraZeneca and Johnson & Johnson are still in

clinical trials. **Related** Vaccines have protected us from deadly pathogens for millennia

Why Vaccines Are Critical To Keeping Diseases At Bay



Scientists around the world are racing to develop a vaccine for the novel coronavirus that has killed tens of thousands of people since late December. Dozens of companies and institutions are leading the charge at a record pace, and some already have begun the first phase of clinical trials. Yet researchers continue to warn that it could take at least a year to 18 months before a vaccine is ready for public use—a long time to wait for what many see as the best hope to stem the spread of the SARS-CoV-2 virus, which causes COVID-19.

Most vaccines don’t cure diseases; they prevent you from getting infected in the first place. Vaccines contain the same germ (or part of a germ) that causes a disease, but in a killed or weakened state so that it doesn’t actually make you sick. The immune system learns about the pathogen, stores information about it, and produces antibodies against it so that the next time it appears, the body can fight it off.

Vaccines have been around only for a couple hundred years, but the concept of inoculating ourselves against diseases has a long history.

The invention of vaccines

Smallpox was one of the early scourges of humankind—and the first and only one to be eradicated with the use of a vaccine. By 430 B.C., humans had figured out that people who survived smallpox developed an immunity to it. Sometime over the next 2,000 years—some say as early as 200 B.C.—people learned how to inoculate themselves against it. Early accounts from China and India in-

dicating that people fought the deadly disease using a technique called variolation, which involved grinding up smallpox scabs and deliberately infecting someone with it by blowing it up a nostril or scratching it into their skin. Variolation caused a milder form of the disease and was far from perfect: Not only was there still a 2 to 3 percent fatality rate, but the infected could pass on smallpox. Still, by the early 18th century, the technique had become popular in Europe and the Americas.



In 1796, an English doctor named Edward Jenner revolutionized the way we approach diseases like smallpox. He showed that inoculation using a weakened strain of cowpox—a mild zoonotic disease that at the time typically transferred from cattle to humans—could also protect against smallpox. During the next several decades, Jenner’s vaccination method gradually replaced variolation. Thanks to that discovery and developments in the ensuing years, smallpox began to fade. In 1980, nearly 200 years later, the World Health Organization (WHO) declared it eradicated.

Jenner’s breakthrough paved the way for vaccines that today prevent widespread epidemics of a variety of diseases, including influenza, measles, polio, rabies, tetanus, typhoid, yellow fever, and cervical cancer.

How vaccines work

Your body’s immune system is designed to seek and destroy invading pathogens—but it’s not always easy, and pathogens can be clever. For example, the flu virus disguises itself as it enters your body and then begins to replicate before your immune system realizes that it’s there. Vaccines give your immune system a leg up in the fight by teaching it how to quickly recognize a pathogen. There are several different types of vac-

cines, but they all essentially serve to introduce a germ or part of a germ into your body in a way that can’t make you sick—though it may cause minor symptoms such as fever as your body builds immunity. Some vaccines use the entire pathogen, but in a killed or weakened state; some use only the parts of the organism that alert the immune system; some use a toxin made by the germ, and some rely on the pathogen’s genetic material.

When you receive a vaccine, the germ sends up an alert to your immune system to start producing antibodies to fight it. Once your immune system has beaten the pathogen, it knows how to quickly destroy it. When you’re exposed to the real thing, your body recognizes the bug and can fight off the infection before it begins.



Sometimes that immunity from a vaccine can last for years or even the rest of your life, while other vaccines require boosters at regular intervals. All adults and children need the influenza vaccine every year to prevent infection against the viral strains likely to be common that season.

Misinformation and waning trust in science and government has spurred an anti-vaccine movement among those who question their safety. Yet vaccines remain as crucial as ever to keeping dangerous diseases such as measles and polio at bay. The WHO estimates that vaccines save two million to three million lives each year.

Many are now pinning their hopes on a vaccine to do the same for the novel coronavirus. But it’s too soon to say when that might be—or what type of vaccine will be most effective against the coronavirus that continues to spread around the world. (Courtesy webmd.com and <https://www.nationalgeographic.com/>)

Kelsey-Seybold is now scheduling VIRTUAL and IN-PERSON appointments!

Alan Chang, M.D., F.A.C.O.G.
Obstetrics and Gynecology
Cantonese and Mandarin
• The Woodlands Clinic
• Kingwood Clinic

Guiying Hu, M.D.
Hematology/Oncology
Mandarin
• Berthelsen Main Campus
• Spring Medical and Diagnostic Center

Jeanie Ling, M.D.
Ophthalmology
Ophthalmic Surgery
Glaucoma Specialist
Mandarin
• Berthelsen Main Campus
• Tanglewood Clinic

Amy En-Hui Chen, M.D.
Family Medicine
Mandarin
• Meyerland Plaza Clinic

Frank Hua, M.D.
Internal Medicine
Mandarin
• Spring Medical and Diagnostic Center

John Tam, M.D.
Internal Medicine
Cantonese and Mandarin
• Fort Bend Medical and Diagnostic Center

Yee-Ru (Amy) Chen, D.O.
Family Medicine
Cantonese, Mandarin, and Taiwanese
• Downtown at The Shops at 4 Houston Center

Kuangzoo Huang, M.D.
Family Medicine
Mandarin
• Meyerland Plaza Clinic

Wayne Tie, M.D.
Ophthalmology
Mandarin
• Berthelsen Main Campus
• Clear Lake Clinic

Charlene Crockett, M.D.
Pediatric Ophthalmology
Mandarin
• Berthelsen Main Campus
• Tanglewood Clinic

Jennifer Lai, M.D.
Pediatrics
Mandarin
• Tanglewood Clinic

Eileen Wu, M.D.
Orthopedic Surgery
Mandarin
• Spring Medical and Diagnostic Center
• The Woodlands Clinic

Philip L. Ho, M.D.
Urology
Mandarin
• Clear Lake Clinic
• Berthelsen Main Campus
• Spring Medical and Diagnostic Center

Jia Lee, O.D.
Optometry
Mandarin
• Spring Medical and Diagnostic Center

Chen Xie, M.D.
Ear, Nose, and Throat
Mandarin
• Berthelsen Main Campus
• Clear Lake Clinic

Joyce Holz, M.D.
Gynecology
Mandarin
• Berthelsen Main Campus

Tri Lee, M.D.
Endocrinology
Cantonese
• Berthelsen Main Campus
• Kingwood Clinic
• Meyerland Plaza Clinic

Beth Yip, M.D., F.A.A.P.
Pediatrics
Cantonese and Mandarin
• Pearland Clinic

Whether you’re new to Kelsey-Seybold or a current patient, you have a choice of where you can safely get care. Call our **24/7** Contact Center at **713-442-0000** to schedule a same-day or next-day virtual **Video Visit** or, for non-respiratory illnesses, an **in-person appointment** at a Kelsey-Seybold Clinic near you.

